The record
Written from the 1 report below. Nothing here is unsourced.
- Dr.
- Reddy’s Laboratories has launched Nivorz, a biosimilar of nivolumab (the reference drug Opdivo), in India.
- The product was developed and manufactured entirely in-house at the company’s biologics facility in Bachupally, Hyderabad, marking Dr.
- Reddy’s entry into biosimilar immuno-oncology in India.
- The company says the launch aims to improve access to immunotherapy through affordable biosimilars.
- India’s immuno-oncology market is estimated at about ₹3,900 crore in 2025, driven mainly by checkpoint inhibitors such as nivolumab.
What to watch next
- Uptake and pricing of Nivorz against existing nivolumab treatments
- Further expansion of Dr. Reddy’s oncology and complex biosimilars portfolio
Who said what2
Only words found exactly in the article are shown, attributed and linked to the line they came from.
Sridevi Khambhampaty
1 quote · 1 outlet
“The launch of Nivorz marks an important milestone for our biologics business. It reinforces our commitment to expanding patient access to high-quality biologic therapies, strengthens our oncology portfolio and reflects our continued focus on developing complex biosimilars.”
In the article
…it reflects the company’s end-to-end capabilities across the biosimilar value chain, from development through commercialisation. Sridevi Khambhampaty, Global Head of Biologics, Dr. Reddy’s Laboratories, said: The launch of Nivorz marks an important milestone for our biologics business. It reinforces our commitment to expanding patient access to high-quality biologic therapies, strengthens our oncology portfolio and reflects our continued focus on developing complex biosimilars. ” “As access to immunotherapy continues to be a challenge for many patients, we remain committed to improving access to high-quality treatment options through affordable biosimilars such as Nivroz,” MV Ramana, CEO -…
MV Ramana
1 quote · 1 outlet
“As access to immunotherapy continues to be a challenge for many patients, we remain committed to improving access to high-quality treatment options through affordable biosimilars such as Nivroz”
In the article
…biologics business. It reinforces our commitment to expanding patient access to high-quality biologic therapies, strengthens our oncology portfolio and reflects our continued focus on developing complex biosimilars.” “ As access to immunotherapy continues to be a challenge for many patients, we remain committed to improving access to high-quality treatment options through affordable biosimilars such as Nivroz ,” MV Ramana, CEO - Global Generics, Dr. Reddy’s Laboratories, said in a release on Tuesday. The immuno-oncology market in India, estimated at about ₹3,900 crore in 2025, is predominantly driven by checkpoint inhibitors…
Related reporting
Grouped by subject or cast while the story boundary is under human review. No chronology is implied.
Loading the story…
Coverage1
All filed from India
Named India · Bachupally · Hyderabad · Opdivo · Dr Reddy's Laboratories · M.V. Ramana · Nivorz · Sridevi Khambhampaty
The 1 report is listed beside the record.
Ask this story
Answers cite the reports above, or say they can't.